secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001274737-23-000101
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen Q3 rev $13.4M, net loss narrows to $5.4M; guides FY rev at least $50M
----------------------------------------------------------------------------

- Revenue $13.4M vs $14.7M YoY (included $3.7M one-time Medicare); net loss $(5.4)M vs $(8.1)M.
- Adj. EBITDA improved to $(3.6)M from $(6.1)M YoY; gross margin 57.4% vs 59.2%.
- Cash $28.4M at Sep 30, $31.4M at Oct 31; AVISE CTD ASP $320.
- FY 2023 guidance: rev ≥$50M (record), adj. EBITDA ~$(20)M; expects improvement in 2024.
- Exclusive license with Johns Hopkins to develop lupus nephritis biomarkers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473723000101/0001274737-23-000101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473723000101/exdx-20231113.htm
  HTML page:      https://secwatch.observer/filing/0001274737-23-000101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer